中文
About Us
Corporate Overview
Sr. Management Team
Board of Directors
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
ASC09
ASC06
Partnership
Investors
Financials & Filings
News
2019
2018
2017
2016
2015
2014
Careers
2019
2018
2017
2016
2015
2014
Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis
2017-08-18
牛牛赌博手机游戏
